Press release
Injectable Drug Delivery Market Analysis 2018: Top Companies are(Pfizer, Gerresheimer, BD, SCHOTT, Bespak, Ypsomed AG, Teva Pharmaceuticals, Terumo Medical Corporation, Sandoz, Eli Lilly and Company, Alkermes, Baxter International Inc.)
Injectable Drug Delivery Market
It is very important to know all market definition, classifications, segments, applications, engagements and market trends to know how the injectable drug delivery market is going to perform in the Forecast years 2018-2025. This report aims to examine the developments of the Global injectable drug delivery market including its market improvement, development, position and others which are done by the key players and brands. This report also contains all the global injectable drug delivery market drivers and restrains which are derived SWOT analyses.
Click Here For Free Sample Report @: http://databridgemarketresearch.com/request-a-sample/?dbmr=global-injectable-drug-delivery-market
Global injectable drug delivery market is expected to reach USD 1,104,096.5 million by 2025 from USD 378,998.2 million in 2017, at a CAGR of 12.4% in the forecast period 2018 to 2025
The major factors contributing to the growth of the market includes factors such rising cases of chronic diseases and due to rising demand of self-injection devices. On the other hand needle stick injuries and infections may hinder the growth of the market.
Covered in this report
The report covers the present scenario and the growth prospects of the global injectable drug delivery market for 2018-2025. To calculate the market size, the report considers the revenue generated from the sales of the web conferencing and unified communication and collaboration (UC&C) and video conferencing, secondary resources and doing in-depth company share analysis of major 10 players in the market.
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
The key market players for global injectable drug delivery market are listed below:
• Baxter International, Inc.,
• Becton Dickinson and Company,
• Gerresheimer AG,
• Pfizer, Inc.,
• Schott AG,
• Alkermes Plc.,
• Eli Lilly and Company,
• Sandoz,
• Terumo Corporation,
• Teva Pharmaceuticals Industries Ltd.
• Ypsomed,
• Bespak
Have Any Query? Ask Our Expert: http://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-injectable-drug-delivery-market
The market is further segmented into:
• Type
• Usage Pattern
• End-User
• Mode of Administration
• Distribution Channel
• Application
• Geography
The global injectable drug delivery market is segmented based on type into two
notable segments; injectable drug delivery device and injectable drug delivery formulation. Injectable drug delivery device market is segmented into conventional injection devices and self-injection devices. The injectable drug delivery formulation is segmented into conventional drug delivery formulation and novel drug delivery formulation.
• The Injectable drug delivery market is dominated by formulations with 75.7% market share in 2018, growing at a CAGR of 12.4% and will cross USD 837,873.64 million by 2025
On the basis of application, the market is segmented into autoimmune disease, hormonal disorders, orphan diseases, oncology and others. The autoimmune diseases segment is further sub segmented based on indications into rheumatoid arthritis, multiple sclerosis, Crohn’s disease, psoriasis and others. Hormonal disorders are further segmented into indications such as diabetes, antithrombotic therapy, reproductive health diseases, anemia, osteoporosis and others.
• The Injectable drug delivery market is dominated by hormonal disorders with 50.1% market share in 2018, growing at a CAGR of 12.1% and will cross USD 540,977.35 million by 2025. However, oncology segment is expected to grow at the highest CAGR of 13.6% in the forecast period, and is expected to reach USD 265,145.17 million in 2025 from USD 82,915.00 million in 2017
On the basis of usage pattern, the market is segmented into curative care, immunization and other usage pattern. The Injectable drug delivery market is dominated by curative care with 93.2% market share in 2018, growing at a CAGR of 12.5% and will cross USD 1,036,829.49 million by 2025.
On the basis of mode of administration, the market is segmented into skin, circulatory/muskoskeletal, organs and central nervous system. The Injectable drug delivery market is dominated by skin with 46.8% market share in 2018, growing at a CAGR of 12.8% and will cross USD 532,193.0 million by 2025.
Questions? We’ll Put You On The Right Path Request Analyst Call @ http://databridgemarketresearch.com/speak-to-analyst/?dbmr=global-injectable-drug-delivery-market
On the basis of end users, the market is classified into hospitals and clinics, home healthcare, research laboratories, pharmaceutical and biotechnological companies and others. The Injectable drug delivery market is dominated by hospitals & clinics with 62.6% market share in 2018, growing at a CAGR of 12.5% and will cross USD 693,323.05 million by 2025.
On the basis of distribution channel, the market is classified into hospital pharmacies, pharmacy store, and direct tender and online pharmacy. The Injectable drug delivery market is dominated by direct tenders with 69.2% market share in 2018, growing at a CAGR of 12.7% and will cross USD 780,682.75 million by 2025. However, pharmacy stores segment is expected to grow at the highest CAGR of 13.5% in the forecast period, and is expected to reach USD 142,617.48 million in 2025 from USD 44,812.56 million in 2017
Based on geography, the market is segmented into 5 geographical regions, North America, Europe, Asia-Pacific, South America and Middle East and Africa. The geographical regions are further segmented into 24 major countries such as U.S. Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Belgium, Turkey, Japan, China, Singapore, Brazil, India, Russia, South Africa and many others.
Based on geography, the Global injectable drug delivery market is segmented into geographical regions, such as,
• North- America
• South America
• Europe
• Asia-Pacific
• Middle East and Africa
TABLE OF CONTENTS GLOBAL INJECTABLE DRUG DELIVERY MARKET
1. INTRODUCTION
1.1. OVERVIEW OF GLOBAL INJECTABLE DRUG DELIVERY MARKET
1.2. CURRENCY AND PRICING
1.3. LIMITATION
1.4. MARKETS COVERED
2. MARKET SEGMENTATION
2.1. MARKETS COVERED
2.2. GEOGRAPHIC SCOPE
2.3. YEARS CONSIDERED FOR THE STUDY
2.4. CURRENCY AND PRICING
2.5. RESEARCH METHODOLOGY
2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7. SECONDARY SOURCES
2.8. ASSUMPTIONS
3. MARKET OVERVIEW
3.1. DRIVERS
3.1.1. RISING CASES OF CHRONIC DISEASES
3.1.2. RISING DEMAND OF SELF-INJECTION DEVICES
3.1.3. GROWTH OF BIOLOGICS MARKET
3.1.4. TECHNOLOGICAL ADVANCEMENTS AND INNOVATIONS IN DRUG DELIVERY MARKET
3.2. RESTRAINTS
3.2.1. NEEDLESTICK INJURIES AND INFECTIONS
3.2.2. HIGH COST OF DEVELOPMENT
3.2.3. STRICT REGULATORY FRAMEWORK
3.3. OPPORTUNITY
3.3.1. INCREASING DEMAND FOR GENERIC AND BIOSIMILAR DRUGS
3.3.1.1. GENERICS
3.3.1.2. BIOSIMILARS
3.3.2. INCREASING DEMAND FOR CONTRACEPTIVE INJECTABLES
3.3.3. INCREASING DEMAND FOR SELF-ADMINISTRATION OF DRUGS
3.4. CHALLENGES
3.4.1. ALTERNATIVE ROUTE OF DRUG ADMINISTRATION
3.4.2. PRODUCT RECALL
3.4.3. STABILITY OF PRODUCTS
3.4.4. STERILITY OF INJECTIONS
4. EXECUTIVE SUMMARY
5. PREMIUM INSIGHTS
6. GLOBAL INJECTABLE DRUG DELIVERY MARKET, REGULATORY
6.1. OVERVIEW
6.2. U.S. FDA APPROVAL
6.3. CE MARKING (EUROPEAN CONFORMITY)
6.4. EM (EUROPEAN MEDICINE AGENCY)
7. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY TYPE
7.1. OVERVIEW
7.2. INJECTABLE DRUG DELIVERY DEVICES
7.2.1. CONVENTIONAL INJECTION DEVICES
7.2.2. SELF INJECTION DEVICES
7.2.2.1. NEEDLE FREE INJECTORS (NFI)
7.2.2.2. AUTO INJECTORS
7.2.2.3. PEN INJECTORS
7.2.2.4. WEARABLE INJECTORS
7.3. INJECTABLE DRUG DELIVERY FORMULATION
7.3.1. CONVENTIONAL DRUG DELIVERY FORMULATIONS
7.3.1.1. SOLUTIONS
7.3.1.2. RECONSTITUTED/LYOPHILIZED FORMULATIONS
7.3.1.3. SUSPENSIONS
7.3.1.4. EMULSIONS
7.3.2. NOVEL DRUG DELIVERY FORMULATIONS
7.3.2.1. COLLOIDAL DISPERSIONS
7.3.2.2. MICROPARTICLES
7.3.2.3. LONG ACTING INJECTION FORMULATION
8. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY APPLICATION
8.1. OVERVIEW
8.2. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY APPLICATION
8.3. HORMONAL DISORDERS
8.3.1. INJECTABLE DRUGS FOR DIABETES
8.3.2. INJECTABLE DRUGS FOR ANEMIA
8.3.3. INJECTABLE DRUGS FOR REPRODUCTIVE HEALTH DISEASE
8.3.4. INJECTABLE DRUGS FOR ANTITHROMBOTIC/THROMBOLYTIC THERAPY
8.3.5. INJECTABLE DRUGS FOR OSTEOPOROSIS
8.3.6. INJECTABLE DRUGS FOR GROWTH HORMONE DISORDERS (GHD)
8.4. ONCOLOGY
8.5. AUTOIMMUNE DISEASES
8.5.1. INJECTABLE DRUGS FOR RHEUMATOID ARTHRITIS
8.5.2. INJECTABLE DRUGS FOR MULTIPLE SCLEROSIS
8.5.3. INJECTABLE DRUGS FOR CROHN’S DISEASES
8.5.4. INJECTABLE DRUGS FOR PSORIASIS
8.5.5. INJECTABLE DRUGS FOR OTHER AUTOIMMUNE DISEASES
8.6. ORPHAN DISEASE
8.7. OTHER APPLICATIONS
8.7.1. INJECTABLE DRUGS FOR PAIN MANAGEMENT
8.7.2. INJECTABLE DRUGS FOR ALLERGY TREATMENT
8.7.3. INJECTABLE DRUGS FOR AESTHETIC TREATMENTS
8.7.4. INJECTABLE DRUGS FOR HEPATITIS C
8.7.5. INJECTABLE DRUGS FOR HEMOPHILIA
9. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN
9.1. OVERVIEW
9.2. CURATIVE CARE
9.3. IMMUNIZATIONS
9.4. OTHER USAGE PATTERN
10. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION
10.1. OVERVIEW
10.2. SKIN
10.3. CIRCULATORY/ MUSKOSKELETAL
10.4. ORGANS
10.5. CENTRAL NERVOUS SYSTEM
11. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY END USER
11.1. OVERVIEW
11.2. HOSPITALS AND CLINICS
11.3. HOME HEALTHCARE SETTINGS
11.4. RESEARCH LABORATORIES
11.5. PHARMACEUTICAL AND BIOTECHNOLOGICAL COMPANIES
11.6. OTHER END USERS
12. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL
12.1. OVERVIEW
12.1.1. HOSPITAL PHARMACY
12.1.2. PHARMACY STORES
12.1.3. DIRECT TENDER
12.1.4. ONLINE PHARMACY
13. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY GEOGRAPHY
13.1. OVERVIEW
13.2. NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET
13.2.1. U.S. INJECTABLE DRUG DELIVERY MARKET
13.2.2. CANADA INJECTABLE DRUG DELIVERY MARKET
13.2.3. MEXICO INJECTABLE DRUG DELIVERY MARKET
13.3. EUROPE INJECTABLE DRUG DELIVERY MARKET
13.3.1. GERMANY INJECTABLE DRUG DELIVERY MARKET
13.3.2. FRANCE INJECTABLE DRUG DELIVERY MARKET
13.3.3. UK INJECTABLE DRUG DELIVERY MARKET
13.3.4. ITALY INJECTABLE DRUG DELIVERY MARKET
13.3.5. SWITZERLAND INJECTABLE DRUG DELIVERY MARKET
13.3.6. SPAIN INJECTABLE DRUG DELIVERY MARKET
13.3.7. NETHERLAND INJECTABLE DRUG DELIVERY MARKET
13.3.8. RUSSIA INJECTABLE DRUG DELIVERY MARKET
13.3.9. TURKEY INJECTABLE DRUG DELIVERY MARKET
13.3.10. BELGIUM INJECTABLE DRUG DELIVERY MARKET
13.3.11. REST OF EUROPE INJECTABLE DRUG DELIVERY MARKET
13.4. APAC INJECTABLE DRUG DELIVERY MARKET
13.4.1. JAPAN INJECTABLE DRUG DELIVERY MARKET
13.4.2. CHINA INJECTABLE DRUG DELIVERY MARKET
13.4.3. SOUTH KOREA INJECTABLE DRUG DELIVERY MARKET
13.4.4. INDIA INJECTABLE DRUG DELIVERY MARKET
13.4.5. AUSTRALIA INJECTABLE DRUG DELIVERY MARKET
13.4.6. SINGAPORE INJECTABLE DRUG DELIVERY MARKET
13.4.7. THAILAND INJECTABLE DRUG DELIVERY MARKET
13.4.8. MALAYSIA INJECTABLE DRUG DELIVERY MARKET
13.4.9. INDONESIA INJECTABLE DRUG DELIVERY MARKET
13.4.10. PHILIPPINES INJECTABLE DRUG DELIVERY MARKET
13.4.11. REST OF APAC INJECTABLE DRUG DELIVERY MARKET
13.5. SOUTH AMERICA INJECTABLE DRUG DELIVERY MARKET
13.5.1. BRAZIL INJECTABLE DRUG DELIVERY MARKET
13.5.2. REST OF SOUTH AMERICA INJECTABLE DRUG DELIVERY MARKET
13.6. MEA INJECTABLE DRUG DELIVERY MARKET
13.6.1. SOUTH AFRICA INJECTABLE DRUG DELIVERY MARKET
13.6.2. REST OF MEA INJECTABLE DRUG DELIVERY MARKET
14. GLOBAL INJECTABLE DRUG DELIVERY MARKET, COMPANY SHARE
14.1. COMPANY SHARE ANALYSIS: GLOBAL
15. COMPANY PROFILES
15.1. BECTON, DICKINSON AND COMPANY
15.2. PFIZER
15.3. BAXTER INTERNATIONAL
15.4. GERRESHEIMER AG
15.5. SCHOTT AG INC.
15.6. ALKERMES INC.
15.7. ANTARES PHARMA
15.8. BESPAK (SUBSIDIARY OF CONSORT MEDICAL COMPANY)
15.9. ELCAM MEDICAL
15.10. ELI LILLY AND COMPANY
15.11. HASELMEIER
15.12. MYLAN N.V.
15.13. NOVO NORDISK
15.14. OWEN MUMFORD LTD
15.15. SANDOZ INTERNATIONAL GMBH
15.16. SANOFI
16. RELATED REPORTS
To Understand Complete Table Of Content, Tables And Figures @ https://databridgemarketresearch.com/toc/?dbmr=global-injectable-drug-delivery-market
Other Market Insights:
North America injectable drug delivery market is expected to reach USD 354.5 billion by 2024 from USD 154.0 billion in 2016, at a CAGR of 11.0% in the forecast period 2017 to 2024.
Read More: http://databridgemarketresearch.com/reports/north-america-injectable-drug-delivery-market/
About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: sopan.gedam@databridgemarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Injectable Drug Delivery Market Analysis 2018: Top Companies are(Pfizer, Gerresheimer, BD, SCHOTT, Bespak, Ypsomed AG, Teva Pharmaceuticals, Terumo Medical Corporation, Sandoz, Eli Lilly and Company, Alkermes, Baxter International Inc.) here
News-ID: 1227549 • Views: …
More Releases from Data Bridge Market Research
Vitamin K Market IS growing at a CAGR of 6.8% during the forecast period of 2023 …
Vitamin K Market Analysis and Size
The essential factors contributing to the growth of the market in the forecast period of 2023 to 2020 include growing demand for vitamin supplements, changing dietary patterns, and rising health consciousness.
Data Bridge Market Research analyses that the global vitamin K market, which was USD 841.47 million in 2022, is expected to reach USD 1,410.20 million by 2030, growing at a CAGR of 6.8% during the…
Transformer Oil Market is expected to undergo a CAGR of 7.55% by 2029
Transformer Oil Market Analysis and Size
Transformers are almost everywhere, and every power and distribution transformer is filled with the dielectric insulating fluid, which consists high resistance to electricity and cools the transformer. The "bio based oil" is the highest growing type segment because it has better resistance to fire as compared to other oil over the forecast period. Furthermore, the growth of electric grids in developing economies and the upgradation…
Fatty Alcohols Market is expected to undergo a CAGR of 5.15% by 2029
Fatty Alcohols Market Analysis and Size
The rising demand of hygiene product coupled with growing consumer awareness is anticipated to drive the personal care industry and boost the growth of the fatty alcohols market. Fatty alcohols are used as emollients, emulsifiers and catalytic hydrogenation in cosmetics and beauty products. The "C11-C14 fatty alcohols" is the fastest growing product segment because it is used to produce sodium laureth ether sulphate (SLES), a major foaming agent…
Exclusive Insights on Gusseted Bags Market Latest Trends, Drivers, Strategies an …
An important Gusseted Bags Market research report is produced by taking into account every requirement that organizations need to meet in order to expand successfully. This market report forecasts the market size based on data on major retailer sales, industry growth by upstream and downstream factors, industry advancement, major players, market segments, and application. When creating the reliable Gusseted Bags Market study, the goals of the marketing research are taken into…
More Releases for DRUG
Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions.
Alcohol abuse and drug…
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.
Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes…
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Introduction to Hepatitis Disease
1.1 Prologue
1.1.1 History of Hepatitis
1.1.2 Causes of Hepatitis Disease
1.2 Types of Viruses which are Responsible for Hepatitis Disease
2. Global Prevalence of Hepatitis Infection
3. Available Drug Classes for Hepatitis Disease Treatment
3.1 Interferon Alfa Therapy
3.2 Protease Inhibitors Therapy
3.3 Polymerase…
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Indispensable Advent of Microcapsules
1.1 Trajectory of Microencapsulation
1.2 Why and wherefores for Microencapsulation
2. Characterization of Microcapsules
2.1 Composition of Microcapsules
2.2 Parameters Influencing Microcapsules
3. Engineering Technology of Microcapsules
3.1 Physical Manufacturing Technologies
3.2 Physicochemical and Chemical Technologies
4. Applicability of Microcapsules
4.1 Microcapsules in Pharmaceuticals
4.2 Microcapsules in Nutraceuticals
…
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug
European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning…
Drug Discovery Strategies, PBPK Modeling and Drug-Drug Interaction Explored and …
This year’s 12th annual ADMET conference and exhibition promises to deliver appearances from experienced pharmaceutical professionals from ADME and PK/PD organisations such as AbbVie, GSK, Roche and Bayer when it returns to London this June.
The carefully selected speaker line up will be addressing early ADME application strategies and discussing the latest technologically advanced screening and testing models along with exploring ADMET technologies which will identify properties of a drug…
